These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 17716136)

  • 21. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M; Lijnen HR; Keber D; Collen D
    Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.
    Chung TW; Wang SS; Tsai WJ
    Biomaterials; 2008 Jan; 29(2):228-37. PubMed ID: 17953984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes.
    Tiukinhoy-Laing SD; Huang S; Klegerman M; Holland CK; McPherson DD
    Thromb Res; 2007; 119(6):777-84. PubMed ID: 16887172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro sonothrombolysis of human blood clots with BR38 microbubbles.
    Petit B; Gaud E; Colevret D; Arditi M; Yan F; Tranquart F; Allémann E
    Ultrasound Med Biol; 2012 Jul; 38(7):1222-33. PubMed ID: 22542261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
    Ferres H
    Drugs; 1987; 33 Suppl 3():33-50. PubMed ID: 3315613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombolytic therapy.
    Collen D; Stump DC; Gold HK
    Annu Rev Med; 1988; 39():405-23. PubMed ID: 3130773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sonothrombolysis is effective with recombinant tissue-type plasminogen activator, but not with Abciximab. Results from an in vitro study with whole blood clots and platelet-rich clots.
    Eggers J; Ossadnik S; Hütten H; Seidel G
    Thromb Haemost; 2009 Dec; 102(6):1274-7. PubMed ID: 19967161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clot-Targeted Nanogels for Dual-Delivery of AntithrombinIII and Tissue Plasminogen Activator to Mitigate Disseminated Intravascular Coagulation Complications.
    Sheridan A; Nellenbach K; Pandit S; Byrnes E; Hardy G; Lutz H; Moiseiwitsch N; Scull G; Mihalko E; Levy JH; Brown AC
    ACS Nano; 2024 Jun; 18(24):15517-15528. PubMed ID: 38836363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome.
    Bembenek JP; Niewada M; Siudut J; Plens K; Członkowska A; Undas A
    Thromb Haemost; 2017 Jun; 117(7):1440-1447. PubMed ID: 28382369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The t-PA-encapsulated PLGA nanoparticles shelled with CS or CS-GRGD alter both permeation through and dissolving patterns of blood clots compared with t-PA solution: an in vitro thrombolysis study.
    Wang SS; Chou NK; Chung TW
    J Biomed Mater Res A; 2009 Dec; 91(3):753-61. PubMed ID: 19051299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
    Farrehi PM; Zhu Y; Fay WP
    J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action of fibrinolytic enzymes in vivo.
    Ambrus JL; Weber FJ; Ambrus CM
    J Med; 1979; 10(1-2):99-119. PubMed ID: 158624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
    Hauptmann J; Glusa E
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin.
    Hantgan RR; Jerome WG; Hursting MJ
    Blood; 1998 Sep; 92(6):2064-74. PubMed ID: 9731064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy.
    Sun M; Hao Pontius MH; Yang S; Pendekanti T; Raghunathan S; Shavit JA; Sen Gupta A
    J Thromb Haemost; 2023 Apr; 21(4):983-994. PubMed ID: 36696210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
    von dem Borne PA; Cox LM; Bouma BN
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic fibrinolysis: The combined effects of tissue plasminogen activator and recombinant staphylokinase in vitro.
    Aisina R; Mukhametova L; Varfolomeyev S
    Biochim Biophys Acta; 2016 Apr; 1860(4):629-35. PubMed ID: 26723174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.